ActiveNCT05817110

Prospective Realworld Cohort Study to Validate Effectiveness of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule Multicentric, Multinational, Prospective, Observational Study.

Sponsor: AstraZeneca

Trial Details

ConditionLung Malignancy
InterventionParticipant Cohort
StatusActive
Participants712
Est. Completion6 Dec 2026
Last Updated22 May 2026

Primary Outcome

To estimate the positive and negative predictive values of qXR LNMS (lung nodule malignancy score ) in a multi-centre real-world setting.

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Male or female patients aged \>35 years * Patients diagnosed with incidental pulmonary nodule (IPN) on CXR (chest x-ray) by qXR and confirmed by the radiologist at the site with nodule size ≥8 and ≤30 mm. Exclusion Criteria: * Any medical or other contraindications for a CT scan * Nondigital (chest x-ray)CXR * CT scan is done more than 6 months after (chest x-ray) CXR * Patients with already diagnosed lung cancer * The patients referred for an X-Ray for a suspicious Lung cancer * A patient who already participated in the study.

Trial Sites

Countries

EgyptIndiaIndonesiaMexicoTurkey (Türkiye)
View Registry Entry

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service